检测淋巴结中ERCC1蛋白指导非小细胞肺癌的个体化治疗  

Detection of ERCC1 protein in lymph nodes for guiding individualized therapy in advanced non-small cell lung cancer

作　　者：朱建荣[1] 万小蔹[1] 崔小川[1] 郁震[1] 

机构地区：[1]南京医科大学附属无锡市人民医院呼吸科,江苏无锡214023

出　　处：《中国癌症防治杂志》2013年第4期328-332,共5页CHINESE JOURNAL OF ONCOLOGY PREVENTION AND TREATMENT

摘　　要：目的探讨转移淋巴结中核苷酸切除修复交叉互补基因1(excision repair cross-complementation group1,ERCC1)蛋白的表达情况,以指导非小细胞肺癌(non-small cell lung cancer,NSCLC)进行个体化治疗的价值。方法 96例通过淋巴结病理组织检查确诊为NSCLC的患者,分为标准治疗组38例,选择含铂类药物的一线化疗方案化疗;个体化治疗组58例,根据转移淋巴结组织中ERCC1蛋白的表达情况选择个体化化疗方案治疗。分析比较两个治疗组的化疗效果,以Kaplan-Meier法分析两个治疗组患者生存期的差异。结果在患者转移淋巴结中ERCC1蛋白表达的阳性率为51.7%。个体化治疗组和标准治疗组的化疗有效率分别为58.6%和34.2%(P=0.019),两组的中位生存期分别为9个月和7个月,个体化治疗组的疗效明显优于标准治疗组(P=0.039)。结论检测淋巴结中ERCC1蛋白的表达以指导NSCLC个体化治疗可以提高化疗效果,延长患者的生存时间。Objective To detect expression of excision repair cross-complementation group I（ERCC1 ） protein in metastatic lymph nodes of patients with advanced non-small cell lung cancer （NSCLC）,and investigate whether the expression can be useful for individualizing therapy. Methods A total of 96 patients with pathologically proven NSCLC involving lymph node metastasis were randomized between one group receiving standard treatment group（n=38）,which was first-line platinum-based chemotherapy;and another group receiving individualized treatment（n=58）, based on ERCC1 protein detection.Treatment effectiveness and Kaplan-Meier survival curves were compared between the two groups. Results ERCC1 protein was expressed in the metastatic lymph nodes of 51.7% of 58 cases.The response rate was significantly higher in the individualized treatment group（58.6% ） than in the standard treatment group （34.2% ,P=0.019）,as was median overall survival （9 vs 7 months,P=0.039）. Conclusions Individualized therapy based on ERCC1 protein detection in metastatic lymph nodes was associated with greater curative effect and survival than was standard therapy.

关 键 词：肺肿瘤 非小细胞肺癌 核苷酸切除修复交叉互补基因1 个体化治疗 

分 类 号：R734.2[医药卫生—肿瘤]